AGILITY FROM DESIGN TO MANUFACTURING
Our Ambifect® Fc-fusion protein platform makes Akston a foundational player in pet health—but that’s just the start of our innovative process.
Our innovations mean nothing until they get to the pets who need them. Ambifect®—an inherently scalable, high-yielding platform that’s well known to regulators—helps us cut the cost, time, and risk of developing new products.
From there, we own the entire development process—labs and manufacturing included—to work towards advancing candidates through the development process as quickly and cost-effectively as possible.
The Ambifect® advantage
Generating species-specific therapeutics for a wide variety of diseases, Ambifect® can tailor immune system interaction and deliver increased duration of action across our pipeline. With Ambifect®, Akston works towards:
Producing a wide variety of therapeutics, including immuno-enhancing proteins and targeted precision proteins
Customizing how a therapy interacts with its disease target and the immune system
Designing, synthesizing, and testing therapies more quickly and cost-effectively
Our
manufacturing
infrastructure
Ambifect® forms the foundation of Akston’s approach to innovation in pet health. We’re vertically integrated from discovery through manufacture with deep involvement in clinical trials. We also manage quality control and cost by owning the key manufacturing infrastructure, including a commercial biologics facility dedicated to pet health.
Our
manufacturing footprint
Our novel therapies are designed and developed at our 20,000-square-foot production facility in Beverly, MA. The facility includes a commercial biologics area with a production-scale process development space and a quality control laboratory, all under a comprehensive quality management system.
Deep partnerships
From established veterinary pharmaceutical companies to startups, we collaborate with partners to advance the development of protein therapeutics.
Interested in a partnership opportunity? Contact us today.